For instance, using a CML-mouse model, Shan et al. demonstrated that the inhibition of BCR::ABL1 with TKIs, combined with inhibition of the RAS pathway using trametinib, an FDA-approved MEK inhibitor, synergistically induced cell death in BCR::ABL1-independent MAPK pathway-driven imatinib-resistant CML stem cells [58]. Here, MAP2K7 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.